Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $97M
Founded date: 2019
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.08.2021 | Series B | $58M | - |
| 21.11.2019 | Series A | $39M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 19.08.2021 | Immunitas Therapeutics Closes $58M in Series B Financing | Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed ... | finsmes.co... |
| 19.08.2021 | Daily funding roundup - August 19th, 2021 | Postman raised $225M, MobileCoin secures $66M, One landed $40M; Rapid Robotics picks up $36.7M Post... | vator.tv/n... |
| 18.08.2021 | An important takeaway from Maven Clinic’s $1 billion valuati... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 18.08.2021 | An important takeaway from Maven Clinic’s $1 billion valuati... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 18.08.2021 | Bayer, Novartis-backed Immunitas secures $58M series B to pu... | Initially backed by Novartis and Bayer's venture arms, immuno-oncology biotech Immunitas has secured... | fiercebiot... |
| 18.08.2021 | Immunitas Therapeutics Completes $58 Million Series B Financ... | WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a si... | prnewswire... |
| 18.08.2021 | Immunitas Therapeutics Completes $58 Million Series B Financ... | - | solasta-ve... |
| 18.08.2021 | Immunitas Therapeutics Scores $58M Series B | WALTHAM, MA, Immunitas Therapeutics, a biotechnology company, announced $58M in a Series B funding... | vcnewsdail... |
| 18.08.2021 | Bayer, Novartis-backed Immunitas secures $58M series B to pu... | Initially backed by Novartis and Bayer's venture arms, immuno-oncology biotech Immunitas has secured... | fiercebiot... |
| 02.03.2021 | Applied BioMath, LLC Announces Collaboration with Immunitas ... | CONCORD, Mass., March 2, 2021 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the indust... | prnewswire... |
Show more